Veracyte Investor Relations Material
Latest events
Q1 2024
Veracyte
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Veracyte Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Testing revenue
Biopharmaceutical and other revenue
Product revenue
Expenses by
Financials
Veracyte, Inc. develops and commercializes blood tests for the early detection of lung cancer and emphysema. The company offers Veracyte Drug Screening Assay and Veracyte Acute Exacerbation Panel (V-AEP) for the detection of Lung Cancer and Chronic Obstructive Pulmonary Disease (COPD). Its drug screening assays are based on a proprietary approach of analyzing patient genomic data to predict which patients are most likely to have cancer after receiving a lung CT scan. The company markets its products through direct sales force, as well as through clinical laboratory partners, medical practitioners, and directly to patients.
Key slides for Veracyte Inc
Q4 2023
Veracyte Inc
Q1 2024
Veracyte Inc
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
VCYT
Country
🇺🇸 United States